About BioAtla
BioAtla is a publicly listed company based in San Diego (United States) founded in 2007. It operates as an immunotherapies for cancer are developed using conditionally active biologics platform. It operates on a HealthTech model. BioAtla has raised $162.31 million across 5 funding rounds from investors including HHS, Janus Henderson Investors and Farallon Capital Management. The company has 76 employees. Its website bioatla.com draws about 15 thousand monthly visits. BioAtla offers products and services including Conditionally Active Biologics (CAB). Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is BioAtla, Inc. Its competitors include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
BioAtla, a San Diego-based biopharmaceutical company, is focused on developing safer and more effective drugs for cancer treatment. Its proprietary Conditionally Active Biologics (CAB) platform is utilized to create antibodies that activate under specific physiological conditions, targeting the unique microenvironment of diseased tissue. Solutions are provided for improved therapeutic outcomes in the oncology sector.
- Headquarters San Diego, United States
- Employees 76
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website bioatla.com
- Social LinkedIn
- Legal Name Bioatla, Inc.
- Annual Revenue$11 M (USD)0as on Dec 31, 2024
- Net Profit-$69.78 M (USD)43.48as on Dec 31, 2024
- EBITDA-$73.02 M (USD)43.16as on Dec 31, 2024
- Total Equity Funding$162.31M (USD)
in 5 rounds
- Latest Funding Round$72.5M (USD), Series D
Jul 2020
- InvestorsHHS
& 7 more
- Employee Count76
Products & Services of BioAtla
BioAtla offers a comprehensive portfolio of products and services, including Conditionally Active Biologics (CAB).
Therapeutics are developed for targeted cancer treatment activation.
Funding Insights of BioAtla
BioAtla has successfully raised a total of $162.31M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $72.5 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $162.31M
- Total Rounds 5
- Last Round Series D — $72.5M
- First Round $5.81M
(Apr 2014)
- Investors Count 8
All 5 funding rounds of BioAtla with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $72.5M | Series D | – | Soleus Capital, HBM Healthcare Investments | |
| Apr 2016 | $220,268 | Grant | – | – | |
| Jan 2016 | $45M | Series B | – | – | – |
| Jul 2015 | $39M | Series B | – | – | – |
| Apr 2014 | $5.81M | Series A | – | – | – |
8 investors in total: 8 institutional.
Investors in BioAtla
BioAtla has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Janus Henderson Investors and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | soleuscapital.com | - | |
Venture capital is focused on healthcare by Pfizer's investment arm. | – | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | |
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
VC firm focusing on life science sector | – | pappas-capital.com | Durham, United States | |
Biotech startups are funded by this venture capital firm. | – | boxercap.com | San Diego, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for BioAtla
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioAtla
32 people are tracked at BioAtla (12 in leadership, 9 in board & advisors, 11 in team); the tracked headcount is 76.
| Name | Role | Group |
|---|---|---|
Richard Waldron | Chief Financial Officer | Leadership |
Jay Short | Chairman, Chief Executive Officer & Cofounder | Leadership |
Eric Sievers | Chief Medical Officer | Leadership |
Michael Melnick | VP, CMC | Leadership |
Sheri Lydick | Chief Commercial Officer | Leadership |
Lisa M. Pelton | Director Of Accounting & Assistant Controller | Leadership |
Jian Chen | Director, Translational Research And Preclinical Development | Leadership |
Kartik Aysola M.d. | Executive Director, Head Of Medical Affairs | Leadership |
Judith Llorin-Sangalang | Executive Medical Director | Leadership |
Charles Lu | Director Of Quality Assurance | Leadership |
Gerlee Thomas | Head Of Regulatory Affairs | Leadership |
Leticia Camacho | Associate Director Medical Writer | Leadership |
Mary Ann Gray | Board Member | Board & advisors |
Sylvia McBrinn | Board Member | Board & advisors |
Susan Moran | Board Member | Board & advisors |
Lawrence Fong | Advisor | Board & advisors |
Michael Manyak | Advisor | Board & advisors |
Padmanee Sharma | Advisor | Board & advisors |
Eddie Williams | Member Board Of Directors | Board & advisors |
Lawrence Steinman | Board Member | Board & advisors |
12 more people are available in the full profile.
Complete people profiles for BioAtla
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BioAtla
BioAtla is a publicly listed company on the NASDAQ with ticker symbol BCAB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Dec 2020
- Listed onNASDAQ: BCAB
- Listed entityBioAtla, Inc.
- Exchange sectorHealth technology
Timeline of BioAtla
4 dated milestones of BioAtla across 13 years, from founding to its latest funding, stage changes and deals.
- Founded BioAtla is founded.
- Funding First funding round of $5.8M.
- Funding Latest funding round, Series D, of $72.5M.
- IPO Lists on the stock exchange (IPO).
Competitors of BioAtla
BioAtla has 9 listed competitors in our database, 8 of them funded. They include Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of BioAtla
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioAtla
The website of BioAtla (bioatla.com) receives about 15.1K visits a month.
- Monthly visits15.1K
▲ 31.1% vs previous month
Websites whose visitors overlap most with BioAtla. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| decode.com | 100% | 13.6K | #1,966,785 | View details | |
| gtptech.com | 100% | – | – | View details | |
biomethodes.com | biomethodes.com | 100% | – | – | – |
| lark.com | 100% | 134.7K | #279,462 | View details | |
| biaffin.com | 100% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for BioAtla
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as BioAtla (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioatla
Complete news archive for BioAtla
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioAtla
BioAtla was founded in 2007 and raised its 1st funding round 7 years after it was founded.
BioAtla is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
BioAtla is a funded company, having raised a total of $162.31M across 5 funding rounds to date. The company's 1st funding round was a Series A of $5.81M, raised on Apr 2014.
BioAtla has 76 employees.
Annual revenue of BioAtla is $11M as on Dec 31, 2024.
BioAtla, a San Diego-based biopharmaceutical company, is focused on developing safer and more effective drugs for cancer treatment. Its proprietary Conditionally Active Biologics (CAB) platform is utilized to create antibodies that activate under specific physiological conditions, targeting the unique microenvironment of diseased tissue. Solutions are provided for improved therapeutic outcomes in the oncology sector.
BioAtla's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
BioAtla offers Conditionally Active Biologics (CAB).
Yes, BioAtla is publicly traded on NASDAQ under the ticker symbol BCAB.
BioAtla has 8 investors. Key investors include HHS, Janus Henderson Investors, Farallon Capital Management, HBM Healthcare Investments, and Soleus Capital.
BioAtla operates through Bioatla, Inc..